Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celsion Corporation    CLSN

CELSION CORPORATION

(CLSN)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

CELSION CORP : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/14/2019 | 04:50pm EDT

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2019, Celsion Corporation (the "Company") issued a press release reporting its financial results for the quarter ended June 30, 2019. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

On August 8, 2019, the Company announced it would hold a conference call on August 15, 2019 to discuss its financial results for the quarter ended June 30, 2019 and provide a business update. The conference call will also be broadcast live on the internet at http://www.celsion.com.

The information in this report, including the exhibit hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. Such information shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

The press release contains forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Please refer to the cautionary note in the press release regarding these forward-looking statements.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.



Exhibit
  No.     Description

 99.1       Press Release titled "Celsion Corporation Reports Second Quarter 2019
          Financial Results and Provides Business Update" issued by Celsion
          Corporation on August 14, 2019.

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELSION CORPORATION
08/14CELSION : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
08/14CELSION CORP : Results of Operations and Financial Condition, Financial Statemen..
AQ
08/14Celsion Corporation Reports Second Quarter 2019 Financial Results and Provide..
GL
08/13Celsion Announces Publication of Results of National Institutes of Health (NI..
GL
08/09Celsion's GEN-1 Immunotherapy Highlighted in Oppenheimer's Expert Call on Ova..
GL
08/08Celsion Corporation to Hold Second Quarter 2019 Financial Results Conference ..
GL
08/05Celsion Announces Data Lock for First Interim Analysis in OPTIMA Phase III St..
GL
06/21CELSION : Announces IRB Approval to Begin a Clinical Study of ThermoDox Plus Hig..
AQ
06/20Celsion Announces IRB Approval to Begin a Clinical Study of ThermoDox® Plus H..
GL
05/15CELSION : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
More news
Financials (USD)
Sales 2019 0,51 M
EBIT 2019 -21,7 M
Net income 2019 -15,5 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -2,35x
P/E ratio 2020 -2,06x
Capi. / Sales2019 75,9x
Capi. / Sales2020 77,4x
Capitalization 38,7 M
Chart CELSION CORPORATION
Duration : Period :
Celsion Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELSION CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 9,00  $
Last Close Price 1,81  $
Spread / Highest target 397%
Spread / Average Target 397%
Spread / Lowest Target 397%
EPS Revisions
Managers
NameTitle
Michael H. Tardugno Chairman, President & Chief Executive Officer
Jeffrey Wayne Church CFO, Secretary & SVP-Investor Relations
Nicholas Borys Chief Medical Officer & Senior Vice President
Khursheed Anwer Chief Scientific Officer & Executive VP
Pok Yu Chow Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELSION CORPORATION28.37%39
GILEAD SCIENCES2.49%81 192
VERTEX PHARMACEUTICALS12.90%48 089
REGENERON PHARMACEUTICALS-20.11%32 649
GENMAB28.62%13 270
NEUROCRINE BIOSCIENCES, INC.36.17%9 041